Certara, Inc.

NasdaqGS:CERT Stock Report

Market Cap: US$2.0b

Certara Past Earnings Performance

Past criteria checks 2/6

Certara has been growing earnings at an average annual rate of 3.2%, while the Healthcare Services industry saw earnings growing at 16.5% annually. Revenues have been growing at an average rate of 11% per year. Certara's return on equity is 0.7%, and it has net margins of 2%.

Key information

3.16%

Earnings growth rate

6.78%

EPS growth rate

Healthcare Services Industry Growth1.72%
Revenue growth rate10.99%
Return on equity0.75%
Net Margin1.97%
Last Earnings Update30 Jun 2025

Recent past performance updates

Shareholders Will Be Pleased With The Quality of Certara's (NASDAQ:CERT) Earnings

Aug 14
Shareholders Will Be Pleased With The Quality of Certara's (NASDAQ:CERT) Earnings

Recent updates

A Look At The Fair Value Of Certara, Inc. (NASDAQ:CERT)

Sep 04
A Look At The Fair Value Of Certara, Inc. (NASDAQ:CERT)

Shareholders Will Be Pleased With The Quality of Certara's (NASDAQ:CERT) Earnings

Aug 14
Shareholders Will Be Pleased With The Quality of Certara's (NASDAQ:CERT) Earnings

Some Investors May Be Worried About Certara's (NASDAQ:CERT) Returns On Capital

Aug 08
Some Investors May Be Worried About Certara's (NASDAQ:CERT) Returns On Capital

Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)

Jul 18
Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)

Is Certara (NASDAQ:CERT) Using Too Much Debt?

Jun 27
Is Certara (NASDAQ:CERT) Using Too Much Debt?
User avatar

FDA Phaseout And AI Integration Will Expand Biosimulation Demand

Regulatory shifts and long-term outsourcing trends are boosting demand for Certara's biosimulation and data-driven modeling solutions, supporting recurring revenue growth and market expansion.

Certara (NASDAQ:CERT) Will Be Hoping To Turn Its Returns On Capital Around

May 07
Certara (NASDAQ:CERT) Will Be Hoping To Turn Its Returns On Capital Around

Certara, Inc.'s (NASDAQ:CERT) 32% Price Boost Is Out Of Tune With Revenues

Apr 15
Certara, Inc.'s (NASDAQ:CERT) 32% Price Boost Is Out Of Tune With Revenues

Buy Certara After The FDA Announcement

Apr 11

Why Certara, Inc. (NASDAQ:CERT) Could Be Worth Watching

Mar 29
Why Certara, Inc. (NASDAQ:CERT) Could Be Worth Watching

Here's Why Certara (NASDAQ:CERT) Can Manage Its Debt Responsibly

Feb 27
Here's Why Certara (NASDAQ:CERT) Can Manage Its Debt Responsibly

Certara, Inc.'s (NASDAQ:CERT) Share Price Not Quite Adding Up

Jan 11
Certara, Inc.'s (NASDAQ:CERT) Share Price Not Quite Adding Up

Is Certara, Inc. (NASDAQ:CERT) Worth US$10.9 Based On Its Intrinsic Value?

Dec 19
Is Certara, Inc. (NASDAQ:CERT) Worth US$10.9 Based On Its Intrinsic Value?

Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return

Nov 15
Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return

Is Certara, Inc. (NASDAQ:CERT) Potentially Undervalued?

Oct 24
Is Certara, Inc. (NASDAQ:CERT) Potentially Undervalued?

Certara (NASDAQ:CERT) Seems To Use Debt Quite Sensibly

Sep 20
Certara (NASDAQ:CERT) Seems To Use Debt Quite Sensibly

Certara: Still Awaiting Consistent Growth

Sep 16

Certara, Inc. (NASDAQ:CERT) Shares Could Be 35% Above Their Intrinsic Value Estimate

Aug 31
Certara, Inc. (NASDAQ:CERT) Shares Could Be 35% Above Their Intrinsic Value Estimate

There's Reason For Concern Over Certara, Inc.'s (NASDAQ:CERT) Price

Jul 18
There's Reason For Concern Over Certara, Inc.'s (NASDAQ:CERT) Price

Certara (NASDAQ:CERT) Is Looking To Continue Growing Its Returns On Capital

Jun 13
Certara (NASDAQ:CERT) Is Looking To Continue Growing Its Returns On Capital

When Should You Buy Certara, Inc. (NASDAQ:CERT)?

Apr 11
When Should You Buy Certara, Inc. (NASDAQ:CERT)?

Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk

Mar 21
Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk

Returns Are Gaining Momentum At Certara (NASDAQ:CERT)

Feb 17
Returns Are Gaining Momentum At Certara (NASDAQ:CERT)

Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth

Jan 30

Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT)

Dec 07
Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT)

Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)

Oct 31
Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)

Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?

Sep 17
Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?

An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued

Aug 30
An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued

Revenue & Expenses Breakdown

How Certara makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:CERT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 25406812536
31 Mar 25394-312436
31 Dec 24385-1212137
30 Sep 24373-3111737
30 Jun 24364-7911238
31 Mar 24361-619537
31 Dec 23354-559434
30 Sep 23353-349433
30 Jun 23352199330
31 Mar 233441410030
31 Dec 22336159728
30 Sep 22324-48728
30 Jun 22314-109526
31 Mar 22301-129323
31 Dec 21286-138820
30 Sep 21275-5813424
30 Jun 21262-5512023
31 Mar 21253-4911121
31 Dec 20244-4910620
30 Sep 20233-16012
30 Jun 2022615812
31 Mar 20215-55712
31 Dec 19209-95312
31 Dec 18164-335110

Quality Earnings: CERT has a large one-off loss of $6.9M impacting its last 12 months of financial results to 30th June, 2025.

Growing Profit Margin: CERT became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CERT has become profitable over the past 5 years, growing earnings by 3.2% per year.

Accelerating Growth: CERT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CERT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare Services industry (13.2%).


Return on Equity

High ROE: CERT's Return on Equity (0.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/01 15:13
End of Day Share Price 2025/10/01 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Certara, Inc. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph VruwinkBaird
Luke SergottBarclays
Andrew MossBofA Global Research